Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ep-475 is a synthetic analog of the thiol proteinase inhibitor E-64. It acts as a potent and selective inhibitor of lysosomal cysteine proteases (thiol proteinases), particularly targeting lysosomal protein degradation pathways. In preclinical studies using isolated rat hepatocytes, Ep-475 was shown to inhibit up to 70% of lysosomal protein degradation at concentrations that do not disturb overall protein synthesis. Additionally, it has demonstrated the ability to reverse calcium-dependent alterations in erythrocyte membranes induced by calcium and calcium activated neutral protease (CANP), suggesting potential utility in modulating red blood cell membrane stability and function[4][5]. There is no evidence that Ep-475 has been developed for clinical use or entered human trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ep-475.